Yes — Peptide Sciences has shut down. On March 6, 2026, the company posted a brief notice on their website confirming they had made the decision to “voluntarily shut down operations and discontinue the sale of all research products.” No advance warning, no explanation, and no clear information about outstanding orders or refunds. The site is now offline, leaving many researchers trying to understand what happened and where to go next. If you’re navigating this shift, it’s important to understand both the broader peptide research landscape and how to evaluate alternative sources moving forward.
If you’re new to peptide research or want a better understanding of how these compounds are used, start here: What Are Peptides? How Peptides Work at the Cellular Level. For a deeper look at how research peptides are produced and what separates high-quality compounds, see: How Peptides Are Created: Natural vs Synthetic and Peptide Shelf Life & Stability
Key Research Facts: Peptide Sciences Shutdown
- Peptide Sciences voluntarily shut down on March 6, 2026 with no advance warning
- The company was reportedly generating approximately $7.4 million in monthly sales as of December 2025
- Over 50 FDA warning letters were sent to research peptide vendors by September 2025
- Independent testing flagged CJC-1295, Tesamorelin, and Retatrutide with E ratings
- In February 2026, HHS announced 14 of 19 restricted peptides would be moved back to Category 1
These shutdowns are part of broader changes happening across the peptide industry in 2026..
What the Shutdown Notice Actually Said
The message Peptide Sciences posted was short — just two sentences. They described the closure as a voluntary decision and thanked customers for their support. That was it. No forwarding address, no refund process, no timeline, no explanation for why.
For a company that had been operating for over a decade and was reportedly generating around $7.4 million in monthly sales as recently as December 2025, the abruptness of the exit shocked a lot of people. Customers who had pending orders, store credit, or outstanding questions got no response. If you have an unfulfilled order, your best option at this point is to contact your bank or credit card provider to initiate a chargeback — don’t wait for a response from Peptide Sciences.
One important warning: scam sites have already been reported attempting to impersonate Peptide Sciences. Any website claiming to be Peptide Sciences after March 6, 2026 is fraudulent. Do not place orders with any site using their branding. For a deeper breakdown of what’s happening across the industry, see our latest analysis on Why Peptide Companies Are Shutting Down and Why Peptide Research Is Growing Worldwide
Why "Voluntary" Is the Most Important Word in Their Statement
The word “voluntarily” in their shutdown notice is telling. It signals a calculated business decision — the company chose to close before regulators arrived, rather than being forced out.
The timing makes the context clear. In the 18 months leading up to the shutdown, federal enforcement against grey-market research peptide vendors escalated dramatically. The FDA issued warning letters to multiple peptide suppliers including Prime Peptides, Xcel Peptides, and SwissChems. In June 2025, FDA agents conducted a physical warehouse raid on a major competitor. By September 2025, more than 50 warning letters had gone out across the industry. In early 2026, the SAFE Drugs Act was introduced, which would prohibit the sale of research chemicals identical to FDA-approved drugs without a New Drug Application.
Peptide Sciences saw where this was headed and got out ahead of it. That’s what “voluntary” means in this context.
The full regulatory timeline — FDA enforcement escalation, the SAFE Drugs Act, and what the reclassification means for research suppliers going forward — is covered in The FDA Peptide Reclassification: What Actually Changed in 2026.
The Regulatory Environment That Led Here
To understand why Peptide Sciences shut down, you need to understand the legal pressure that had been building across the entire research peptide industry.
The core issue is that several peptides sold as “research use only” compounds — particularly GLP-1 analogs like Semaglutide and Tirzepatide — became the targets of active protection by major pharmaceutical companies. When the FDA declared the Semaglutide shortage resolved in February 2025, it removed the legal basis many companies had used to justify compounding GLP-1 peptides. Criminal prosecutions followed. Tailor Made Compounding pleaded guilty to distributing unapproved drugs including BPC-157 and faced a $1.79 million forfeiture. All American Peptide’s owners pleaded guilty to conspiracy charges involving over $3 million in forfeitures.
The message from regulators was unambiguous: selling peptides for human use — regardless of “research use only” disclaimers — could result in prison time and financial ruin. Peptide Sciences, as one of the most visible vendors in the space, faced significant exposure. Shutting down voluntarily was the legally rational move.
To understand why Peptide Sciences shut down, you need to understand the legal pressure that had been building across the entire research peptide industry.
The core issue is that several peptides sold as “research use only” compounds — particularly GLP-1 analogs like Semaglutide and Tirzepatide — became the targets of active protection by major pharmaceutical companies. For a broader look at the legal framework behind this shift, see Are Peptides Legal in the United States?
Were There Quality Issues Too?
Regulatory pressure wasn’t the only problem. Third-party testing data raised questions about product quality at Peptide Sciences, particularly on their newer and higher-profile compounds.
Independent testing platform Finnrick analyzed samples across multiple Peptide Sciences products. Some performed well — BPC-157 scored an A rating, and Ipamorelin averaged 9.2 out of 10 across nine tests. But others failed significantly. CJC-1295 received an E rating. Tesamorelin also received an E. Most notably, Retatrutide — one of their most searched and discussed products — received an E rating based on 37 samples tested between December 2024 and March 2026, with Finnrick flagging a counterfeit detection in November 2025.
Whether quality issues were a factor in the closure decision is unknown — the company made no statement. But the data is worth knowing if you’re evaluating what you may have received from them.
For a framework on verifying compound purity before ordering from any supplier, see How Peptide Purity Is Tested: Understanding COAs and Are Peptides From Chinese Suppliers Safe.
What This Means for the Research Peptide Industry
The shutdown of Peptide Sciences isn’t just about one company. It’s a signal about where the industry is heading.
At least seven research peptide companies shut down in 2025 alone. The grey-market RUO model — selling compounds to consumers under a research-use disclaimer with minimal regulatory oversight — is under more pressure than it has ever been. The FDA has made clear it will enforce against vendors operating this way, and major pharmaceutical companies have demonstrated they will use the courts to protect patented compounds.
That said, the regulatory picture isn’t entirely bleak. In February 2026, HHS Secretary RFK Jr. announced that approximately 14 of 19 previously restricted peptides would be moved back to Category 1 — restoring access to those compounds through licensed compounding pharmacies with a physician’s prescription. Peptides aren’t being banned. The unregulated channel for obtaining them is being shut down. The legitimate, compliant pathway is actually expanding. Read more from our FDA Peptide Reclassification article.
For researchers, this shift means the bar for choosing a supplier is higher than it used to be. Compliance, documentation, and long-term operational stability matter more now than ever.
What to Look for in a Peptide Sciences Alternative
If you’re looking for a replacement supplier, here’s what actually matters right now — not just price or product range, but the factors that determine whether a company will still be operating in 12 months.
Third-party COAs from accredited labs. Not a PDF on a website — verifiable results from an independent lab. This is the baseline quality signal in the current market. BioStrata provides COA documentation for every product in our catalog, available in our COA Library.
Compliance-first operations. Companies that take regulatory compliance seriously are dramatically less likely to disappear overnight. Look for suppliers who are transparent about how they operate, what they sell, and why.
US-based operations. Domestic processing and warehousing supports faster shipping and reduces quality degradation risk from international transit.
No ITC-banned GLP-1 compounds. Any supplier openly selling Semaglutide, Tirzepatide, or Retatrutide as a research chemical right now is a compliance red flag — for their entire operation, not just those products.
BioStrata Research supplies research-grade peptides with full third-party testing documentation, transparent sourcing, and a catalog built around long-term compliance. Browse our Product Page or view our compound-specific research overviews in the Research Library.
For a structured framework on evaluating any research peptide supplier, see How to Evaluate Peptide Vendors and How to Buy Research Peptides: What to Look For.
- CONTINUE LEARNING
Explore Related Peptide Topics
Continue building your understanding by exploring related foundational peptide topics.
References & Sources
- FDA Warning Letters Database — U.S. Food & Drug Administration (FDA)
- Warning Letter to Summit Research Peptides — U.S. Food & Drug Administration, December 2024
- FDA Sends Warning Letters to GLP-1 Compounders — Wilson Sonsini, September 2025
- Rise of Unregulated Peptide Use in Consumer Markets — CNN Health, November 2025
- Why Did Peptide Sciences Close Down? Industry Analysis — Peptide Examiner, March 2026